Predicting engagement in care before and during the COVID-19 pandemic among people with HIV
BACKGROUND: Engagement in care is poor in the US for people with HIV (PWH) and may have been exacerbated by the COVID-19 pandemic. RESEARCH DESIGN AND METHODS: This retrospective, longitudinal study analyzed data from the IQVIA PharMetrics® Plus Claims database to assess engagement in care among PWH in the US 12 months before and during the COVID-19 pandemic (pre- and post-March 1, 2020). Eligible PWH had ≥ 2 medical claims with a HIV-1 diagnosis and continuous health plan enrollment. Three definitions of engagement in care were used: HIV-related healthcare visits, CD4 count/HIV viral load tests, and treatment adherence. Logistic regression compared pre- and during-pandemic engagement in care and identified factors associated with disengagement. RESULTS: < 0.001) during the pandemic for HIV-related healthcare visits (odds ratio [OR] 0.65), laboratory testing (OR 0.55), and treatment adherence (OR 0.90). Strong predictors of disengagement included younger age, being female, insurance type, HIV treatment type, and having a pre-pandemic HIV-related emergency room visit. CONCLUSIONS: Engagement in care for PWH declined during the pandemic, with a variety of characteristics predictive of disengagement. These findings may help to inform interventions and initiatives throughout the HIV care continuum.
Authors
- Ana Urosevic
- François Laliberté (ORCID: https://orcid.org/0000-0003-2601-6214)
- Malena Mahendran (ORCID: https://orcid.org/0000-0002-7313-8268)
- Michael Bogart (ORCID: https://orcid.org/0000-0002-1681-9710)
- Guillaume Germain
- Mei Sheng Duh (ORCID: https://orcid.org/0000-0001-5035-6687)
Institutions
- Gilead Sciences (United States) (US)
- Analysis Group (United States) (US)
Publication Details
- Journal
- Expert Review of Anti-infective Therapy
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1080/14787210.2026.2741263
- Primary Topic
- HIV/AIDS Research and Interventions
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Gilead Sciences